Actuate Therapeutics expands board to 8 directors, appoints former Mersana CEO Martin Huber

Filed May 6, 2026 · Period ending May 1, 2026 · ~1 min read

Key Changes

• medium

  Dr. Martin H. Huber appointed as Class III director effective May 1, 2026, expanding board from 7 to 8 members. Huber was CEO of Mersana Therapeutics until its acquisition by Day One Biopharmaceuticals in January 2026.

  Item 5.02 verify on EDGAR →
• medium

  Huber will provide additional R&D advisory services under separate consulting agreement for $3,000 quarterly, beyond standard board duties, suggesting company values his specific drug development expertise.

  Item 5.02 verify on EDGAR →
• low

  Standard director compensation includes 30,000 stock options vesting over three years and $44,000 annual retainer paid quarterly, plus committee assignment to Nominating and Corporate Governance.

  Item 5.02 verify on EDGAR →